SUBSCRIBE BY RSS rss feed | EMAIL
Natural Solutions Radio header image

AIDS

Rare Treatment Is Reported to Cure AIDS Patient

By DONALD G. McNEIL Jr.

Published: November 13, 2008

Doctors in Berlin are reporting that they cured a man of AIDS by giving him transplanted blood stem cells from a person naturally resistant to the virus.

But while the case has novel medical implications, experts say it will be of little immediate use in treating AIDS. Top American researchers called the treatment unthinkable for the millions infected in Africa and impractical even for insured patients in top research hospitals.

Topics: 

'Assassin' cells home in on HIV

Monday, 10 November 2008

Cells have been successfully engineered in the laboratory to overcome one of HIV's most effective defence mechanisms, say researchers.

The immune system cells, created by UK and US scientists, can lock on to HIV, even after it has mutated to throw them off the scent.

It is hoped the Nature Medicine study could lead to a more effective way of tackling HIV infection.

Tests on people with advanced HIV may start next year.

Topics: 

AIDS claims more rural, black, female populations in Georgia

By CRAIG SCHNEIDER

The Atlanta Journal-Constitution

HIV/AIDS has assumed a new face in Georgia. It is younger and more rural, more likely to be black or female.

And it is harder to reach with prevention messages, testing and services.

Old messages geared to urban, white, gay men simply don’t resonate with many African-American and rural people, advocates say.

That worries the advocates.

Topics: 

<b>HIV Drugs Linked to Increased Risk of Heart Attack

By Steven Reinberg

Posted 4/2/08

WEDNESDAY, April 2 (HealthDay News) -- Two well-known HIV drugs, abacavir and didanosine, appear to increase the risk of heart attacks, European researchers reported Wednesday.

Based on that data, the U.S. Food and Drug Administration is now conducting a safety review of the potential risks of both drugs.

Topics: 

HIV 'hides from drugs for years'

Tuesday, 11 March 2008

HIV can survive the apparently effective onslaught of antiviral drugs for years by hiding away in the body's cells, research shows.

The US National Cancer Institute found low levels of dormant HIV in patients seven years after they started - and responded well to - standard therapy.

The finding confirms patients must take drugs indefinitely, and that any break runs the risk of rekindling infection.

The study features in Proceedings of the National Academy of Sciences.

Topics: 

Male Semen Makes HIV More Potent

By Nikhil Swaminathan

December 14, 2007

More than 80 percent of human immunodeficiency virus (HIV) infections are transmitted via sexual intercourse. And researchers may have discovered at least one reason why. According to a new study published in Cell, a component of human semen may facilitate the spread of the virus by targeting immune system cells, in some cases making the pathogen up to 100,000 times more virulent.

Topics: 

Estimate of AIDS Cases In U.S. Rises

By David Brown

Washington Post Staff Writer
Saturday, December 1, 2007; Page A01

New government estimates of the number of Americans who become infected with the AIDS virus each year are 50 percent higher than previous calculations suggested, sources said yesterday.

For more than a decade, epidemiologists at the Centers for Disease Control and Prevention have pegged the number of new HIV infections each year at 40,000. They now believe it is between 55,000 and 60,000.

Topics: 

Triple-Drug Therapy for HIV Highly Effective

A British study has found that standard triple-drug therapy for HIV infection gives long-term protection against the development of full-flown AIDS,Agence France-Pressereported.

Researchers analyzed data about 7,916 HIV-positive patients on the standard triple-antiretroviral drug therapy, finding that only 167 developed extensive resistance to all three types of medication. The researchers estimated the risk of such triple failure after 10 years of therapy at about 9.2 percent.

The findings appear inThe Lancetmedical journal.

Topics: